Australian & New Zealand Childhood Hematology & Oncology Group Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT03590171
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Australian & New Zealand Childhood Hematology & Oncology Group (Co-Sponsor Australia/NZ) | Australian & New Zealand Children's Haematology/Oncology Group

Active Ingredients

Drugs in Phase 2 Trials (2)

bortezomib (velcade) (1 trial)

panobinostat (farydak) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2